JPMorgan analyst Calvin Sternick initiated coverage of Universal Health with a Neutral rating and $133 price target. 2023 is a transition year for Universal Health, the analyst tells investors in a research note. The firm says the company’s Behavioral growth and margins are expected to recover faster than the acute business where lighter than expected volumes and acuity mix will result in margins flat to slightly down year-over-year. It thinks the stock’s relative risk/reward is less compelling versus peers.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on UHS:
- Universal Health price target lowered to $145 from $168 at Deutsche Bank
- Universal Health price target lowered to $138 from $154 at Wells Fargo
- Universal Health price target lowered to $140 from $144 at Mizuho
- Universal Health price target raised to $130 from $114 at RBC Capital
- Universal Health price target lowered to $140 from $155 at Stephens
